carbonthatcarbonthat
← Every company

Arcutis Biotherapeutics Inc Patents

What Arcutis Biotherapeutics Inc has filed at the patent office — applications as well as grants, because a filing is on the record eighteen months before anyone has to say what it was for.

ARQT on carbonthat →
Filings on file
30
Granted
7
Still pending
23
Filed under
4 names

30 filings

Newest filing first. A pending application has no patent number yet, and most never get one.

InventionPatent
Method for Reducing Side Effects from Administration of Phosphodiesterase-4 InhibitorsA61K 31/44, A61P 19/02, A61K 9/0014, A61K 9/06, A61K 9/122, A61K 45/06, A61K 47/10, A61K 47/24Filed as ARCUTIS BIOTHERAPEUTICS, INC.2026-03-31David W. Osbornepending
METHOD FOR REDUCING SIDE EFFECTS FROM ADMINISTRATION OF PHOSPHODIESTERASE-4 INHIBITORSA61K 31/44, A61P 19/02, A61K 9/0014, A61K 9/06, A61K 9/122, A61K 45/06, A61K 47/10, A61K 47/24Filed as ARCUTIS BIOTHERAPEUTICS, INC.2026-01-09David W. Osborne12685727
PHARMACEUTICAL COMPOSITIONS OF SPIRONOLACTONE FOR DEEP DERMAL DRUG DELIVERYA61K 9/0014, A61K 9/10, A61K 31/585, A61P 17/10, A61P 17/14, A61K 9/009, A61K 9/107, A61K 9/122, A61K 47/20, A61K 47/38Filed as ARCUTIS BIOTHERAPEUTICS, INC.2025-11-03David W. OSBORNEpending
Topical Roflumilast Aerosol FoamsA61K 9/107, A61K 9/124, A61K 31/44, A61K 9/0014, A61K 9/122, A61K 31/165, A61K 31/17, A61K 31/436, A61K 31/4436, A61K 31/513, A61K 31/519, A61K 31/52, A61K 31/593, A61K 31/60, A61K 33/44, A61K 38/13, A61K 47/06, A61K 47/10, A61K 47/14, A61K 47/24, A61K2300/00Filed as ARCUTIS BIOTHERAPEUTICS, INC.2025-10-03David W. OSBORNEpending
SELF-PRESERVING TOPICAL PHARMACEUTICAL COMPOSITIONS COMPRISING DIETHYLENE GLYCOL MONOETHYL ETHERA61K 9/0014, A61K 31/08, A61K 47/548, Y02A 50/30, A61P 31/04, A61K 9/06, A61K 9/107, A61K 31/44, A61K 47/10Filed as ARCUTIS BIOTHERAPEUTICS, INC.2025-09-03David W. OSBORNEpending
METHODS OF TREATMENT USING TOPICAL ROFLUMILAST COMPOSITIONSFiled as ARCUTIS BIOTHERAPEUTICS, INC.2025-06-20DIANE M. HANNApending
PHARMACEUTICAL COMPOSITIONS OF ROFLUMILAST IN AQUEOUS BLENDS OF WATER-MISCIBLE, PHARMACEUTICALLY ACCEPTABLE SOLVENTSA61K 9/0014, A61K 9/06, A61K 31/44, A61K 47/10, A61P 17/06, A61P 17/00, A61P 29/00, A61K 9/0019, A61K 9/12, A61K 9/122, A61K 45/06, A61K2300/00Filed as Arcutis Biotherapeutics, Inc.2025-06-18David W. Osbornepending
TOPICAL ROFLUMILAST FORMULATION HAVING ANTIFUNGAL PROPERTIESA61K 9/122, A61K 31/44, A61P 17/00, A61P 1/00, A61P 17/04, A61P 31/10, A61K 8/69, A61K 9/0014, A61K 9/107, A61K 31/137, A61K 31/201, A61K 31/27, A61K 31/343, A61K 31/4174, A61K 31/4418, A61K 31/496, A61K 31/506, A61K 31/513, A61K 31/60, A61K 33/04, A61K 45/06, A61K 47/06, A61K 47/10, A61K 47/14, A61K 47/24, A61K2300/00, A61Q 3/00, A61Q 5/006, A61Q 5/02, A61Q 19/00Filed as ARCUTIS BIOTHERAPEUTICS, INC.2025-06-12David Reuben BERKpending
METHOD FOR REDUCING SIDE EFFECTS FROM ADMINISTRATION OF PHOSPHODIESTERASE-4 INHIBITORSA61K 31/44, A61P 19/02, A61K 9/0014, A61K 9/06, A61K 9/122, A61K 45/06, A61K 47/10, A61K 47/24Filed as ARCUTIS BIOTHERAPEUTICS, INC.2025-06-02David W. Osbornepending
TOPICAL ROFLUMILAST FORMULATION HAVING IMPROVED DELIVERY AND PLASMA HALF- LIFEA61K 31/44, A61P 17/06, A61K 9/0014, A61K 45/06, A61K 47/06, A61K 47/10, A61K 47/14, A61K 47/24Filed as ARCUTIS BIOTHERAPEUTICS, INC.2025-05-19David W. OSBORNEpending
INHIBITION OF CRYSTAL GROWTH OF ROFLUMILASTA61K 31/44, A61K 9/0014, A61K 9/06, A61K 9/145, A61K 45/06, A61K 47/10, C09K 15/06Filed as ARCUTIS Biotherapeutics, Inc.2025-04-11David W. OSBORNEpending
Roflumilast Formulations with an Improved Pharmacokinetic ProfileA61K 9/0014, A61K 31/44, A61K 9/06, A61K 9/145, A61K 45/06, A61K 47/10, A61K 47/24, C09K 15/06Filed as Arcutis Biotherapeutics, Inc.2024-12-17David Osbornepending
STABLE FORMULATIONS OF SHR0302A61K 9/0014, A61K 31/519, A61P 29/00, A61K 9/113, A61K 31/52, A61K 47/08, A61K 47/12, A61K 47/18, A61K 47/20, A61K 47/34Filed as ARCUTIS BIOTHERAPEUTICS, INC.2024-11-27Herbert R. BRINKMANpending
PHARMACEUTICAL COMPOSITIONS OF ROFLUMILAST AND SOLVENTS CAPABLE OF DISSOLVING HIGH AMOUNTS OF THE DRUGA61K 9/0014, A61K 31/44, A61K 9/06, A61K 9/107, A61K 47/10, A61K 47/14, A61K 47/22Filed as ARCUTIS BIOTHERAPEUTICS, INC.2024-11-09David W. OSBORNEpending
METHODS OF REDUCING ITCH USING TOPICAL ROFLUMILAST COMPOSITIONSFiled as ARCUTIS BIOTHERAPEUTICS, INC.2024-09-13DAVID REUBEN BERKpending
METHODS OF REDUCING ITCH USING TOPICAL ROFLUMILAST COMPOSITIONSA61K 31/44, A61P 17/08, A61P 17/00, A61P 17/04, A61K 9/0014, A61K 9/06, A61K 9/122, A61K 47/08, A61K 47/10, A61K 47/24Filed as ARCUTIS BIOTHERAPEUTICS, INC.2024-09-13David Reuben BERKpending
METHODS OF REDUCING ITCH USING TOPICAL ROFLUMILAST COMPOSITIONSA61K 31/44, A61P 17/08, A61P 17/00, A61P 17/04, A61K 9/0014, A61K 9/06, A61K 9/122, A61K 47/08, A61K 47/10, A61K 47/24Filed as ARCUTIS BIOTHERAPEUTICS, INC.2024-09-13David Reuben BERKpending
DOSING REGIMENS USING TOPICAL ROFLUMILAST COMPOSITIONSA61K 31/44, A61P 17/00, A61K 9/0014, A61K 9/06, A61K 9/107, A61K 9/12, A61K 47/06, A61K 47/10, A61K 47/24Filed as ARCUTIS BIOTHERAPEUTICS, INC.2024-09-06David Reuben BERKpending
DOSING REGIMENS USING TOPICAL ROFLUMILAST COMPOSITIONSFiled as ARCUTIS BIOTHERAPEUTICS, INC.2024-09-06DAVID REUBEN BERKpending
LAURETH-4 CONTAINING TOPICAL FORMULATIONSA61K 9/0014, A61K 31/519, A61P 17/00, A61P 29/00, A61K 9/06, A61K 9/08, A61K 9/107, A61K 31/5377, A61K 31/573, A61K 38/13, A61K 45/06, A61K 47/10, A61K 47/20Filed as ARCUTIS BIOTHERAPEUTICS, INC.2024-08-06David W. OSBORNEpending
TREATMENT OF SKIN CONDITIONS USING HIGH KRAFFT TEMPERATURE ANIONIC SURFACTANTSA61K 9/107, A61K 31/661, A61K 31/683, A61P 17/00, A61P 29/00, A61K 9/0014, A61K 9/06, A61K 31/045, A61K 31/122, A61K 31/165, A61K 31/19, A61K 31/343, A61K 31/37, A61K 31/436, A61K 31/513, A61K 31/519, A61K 31/52, A61K 31/655, A61K 31/662, A61K 35/04, A61K 38/13, A61K 47/06, A61K 47/10, A61K 47/14, A61K 47/24Filed as ARCUTIS BIOTHERAPEUTICS, INC.2024-07-30David W. OSBORNEpending
COMPOSITIONS AND METHODS FOR DEEP DERMAL DRUG DELIVERYA61K 9/107, A61K 31/585, A61P 17/10, A61P 17/14, A61K 9/0014, A61K 9/10, A61K 9/1075, A61K 9/145, A61K 9/146, A61K 31/519, A61K 47/20, A61K 47/24, A61K 47/34, A61K 47/38Filed as ARCUTIS BIOTHERAPEUTICS, INC.2024-07-29David W. OSBORNEpending
METHODS OF TREATMENT USING TOPICAL ROFLUMILAST COMPOSITIONSFiled as ARCUTIS BIOTHERAPEUTICS, INC.2024-06-21Diane M. Hannapending
INHIBITION OF CRYSTAL GROWTH OF ROFLUMILASTA61K 31/44, A61K 9/0014, A61K 9/06, A61K 9/145, A61K 45/06, A61K 47/10, C09K 15/06Filed as ARCUTIS Biotherapeutics, Inc.2024-06-17David W. OSBORNE12336983
METHOD FOR REDUCING SIDE EFFECTS FROM ADMINISTRATION OF PHOSPHODIESTERASE-4 INHIBITORSA61K 31/44, A61P 19/02, A61K 9/0014, A61K 9/06, A61K 9/122, A61K 45/06, A61K 47/10, A61K 47/24Filed as ARCUTIS BIOTHERAPEUTICS, INC.2024-06-17David W. Osborne12697329
Roflumilast Formulations with an Improved Pharmacokinetic ProfileA61K 31/44, A61K 9/0014, A61K 9/06, A61K 9/145, A61K 45/06, A61K 47/10, C09K 15/06Filed as Arcutis Biotherapeutics, Inc.2024-06-17David Osborne12220409
METHOD FOR REDUCING SIDE EFFECTS FROM ADMINISTRATION OF PHOSPHODIESTERASE-4 INHIBITORSA61K 31/44, A61P 19/02, A61K 9/0014, A61K 9/06, A61K 9/122, A61K 45/06, A61K 47/10, A61K 47/24Filed as ARCUTIS BIOTHERAPEUTICS, INC.2024-05-22David W. Osborne12390453
TOPICAL ROFLUMILAST FORMULATION HAVING IMPROVED DELIVERY AND PLASMA HALF- LIFEA61K 31/44, A61P 17/06, A61K 9/0014, A61K 45/06, A61K 47/06, A61K 47/10, A61K 47/14, A61K 47/24Filed as ARCUTIS BIOTHERAPEUTICS, Inc.2024-05-02David W. OSBORNE12310956
TREATMENT OF SKIN CONDITIONS USING HIGH KRAFFT TEMPERATURE ANIONIC SURFACTANTSA61K 9/107, A61K 31/661, A61K 31/683, A61P 17/00, A61P 29/00, A61K 9/0014, A61K 9/06, A61K 31/045, A61K 31/122, A61K 31/165, A61K 31/19, A61K 31/343, A61K 31/37, A61K 31/436, A61K 31/513, A61K 31/519, A61K 31/52, A61K 31/655, A61K 31/662, A61K 35/04, A61K 38/13, A61K 47/06, A61K 47/10, A61K 47/14, A61K 47/24Filed as ARCUTIS BIOTHERAPEUTICS, INC.2024-04-05David W. OSBORNEpending
Roflumilast Formulations with an Improved Pharmacokinetic ProfileA61K 31/44, A61K 9/0014, A61K 9/06, A61K 9/145, A61K 45/06, A61K 47/10, C09K 15/06Filed as Arcutis Biotherapeutics, Inc.2024-03-06David Osborne12011437

Filings are matched to the company by applicant name, so a subsidiary filing under its own name is only here if that name resolves to this company. The applicant is printed as filed, which makes a wrong match visible. A patent is not a product: most applications are never granted, and most grants are never built.

More on ARQT

Company overviewEverything on ARQT in one place, with the price.SEC filingsWhat ARQT's 8-Ks say happened: results, departures, auditor changes.Insider tradingWhat ARQT's own officers and directors buy and sell.Planned salesSales ARQT insiders have filed notice of.Executive payWhat ARQT awarded its chief executive, and what it became.Who owns itEvery manager reporting a position in ARQT.Funds holding itWhich funds and ETFs hold ARQT, and how big a bet.LobbyingWhat ARQT spends lobbying Congress, and on what.Who lobbies for itThe lobbyists on ARQT's account, and who they worked for.

Related datasets

Corporate LobbyingWhat companies spend lobbying Congress, and on what.Lobbying FirmsThe shops companies hire, and who else they represent.Government ContractsWhat federal agencies pay those same companies.Revolving DoorFormer staff now lobbying, and who they worked for.